A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monocolonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.